Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
about
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid ReceptorBeyond serotonin: newer antidepressants in the future.Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and Without Cocaine Dependence.Effects of Chronic Social Defeat Stress on Sleep and Circadian Rhythms Are Mitigated by Kappa-Opioid Receptor Antagonism.Social defeat disrupts reward learning and potentiates striatal nociceptin/orphanin FQ mRNA in rats.Highly Potent and Selective New Diphenethylamines Interacting with the κ-Opioid Receptor: Synthesis, Pharmacology, and Structure-Activity Relationships."Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats".Novel 18F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of 18F-LY2459989 in Nonhuman Primates.Drive and Reinforcement Circuitry in the Brain: Origins, Neurotransmitters, and Projection Fields.Reversal of stress-induced social interaction deficits by buprenorphine.Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(allyl).Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders.Brain mechanisms mediating effects of stress on reward sensitivity
P2860
Q33860286-D0E5EB1E-E1E1-4015-8EEA-1E4FA425A071Q34557706-F3C320B5-E440-4086-A1D7-4E1555955601Q38600702-4929AF2D-1284-4BFB-97B8-7643D9451174Q38695245-847DC3BA-9912-4E6E-A01F-3BAB54228FAFQ38915717-565C658D-CF53-46B4-82E5-820ED51BA880Q41722010-09A4B5AE-D32F-4D6B-AAB1-067304F58288Q44345977-AD99D288-577F-42AD-944F-86EB3AC938C4Q44347602-28188AC3-3596-44AC-A6EB-5E67A428C8C2Q47315933-78E2C2E9-3793-429D-8B73-A915A17517A1Q47659749-BBC2094F-3C0E-4EC2-A745-F1CC30907D3BQ49608912-9BF13660-A75F-4072-8E0B-CBD23BF98D82Q49788866-F40926FA-C6E1-46CB-B44B-EB5F9BFD98A4Q57824506-F400E79C-229D-42E8-BE82-CD27779CA212
P2860
Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
@en
type
label
Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
@en
prefLabel
Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
@en
P2860
P356
P1476
Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
@en
P2093
Andrew D Krystal
William A Carlezon
P2860
P304
P356
10.1002/DA.22500
P577
2016-10-01T00:00:00Z